We hypothesised that because epithelial ovarian cancers containing a germline BRCA1/2 mutation often have a better radiological response to platinum-containing chemotherapy compared to tumours with germline BRCA1/2 wild type, they would also have a better histopathological response to NACT. The gene discussed is BRCA1; the disease is ovarian carcinoma.